T. Rowe Price Associates
CYRX icon

T. Rowe Price Associates’s CryoPort CYRX Stock Holding History

T. Rowe Price Associates’s Portfolio CYRX Stock Details CYRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$835K Buy
100,812
+16,144
+19% +$146K ﹤0.01% 2237
2025
Q4 		$813K Buy
84,668
+17,088
+25% +$161K ﹤0.01% 2167
2025
Q3 		$641K Buy
67,580
+129
+0.2% +$1.09K ﹤0.01% 2278
2025
Q2 		$504K Buy
67,451
+5,868
+10% +$36.4K ﹤0.01% 2297
2025
Q1 		$375K Buy
61,583
+1,580
+3% +$10.9K ﹤0.01% 2372
2024
Q4 		$467K Buy
60,003
+4,902
+9% +$36.5K ﹤0.01% 2312
2024
Q3 		$447K Buy
55,101
+1,499
+3% +$12.3K ﹤0.01% 2298
2024
Q2 		$371K Buy
53,602
+5,080
+10% +$68.4K ﹤0.01% 2313
2024
Q1 		$859K Buy
48,522
+1,438
+3% +$22.8K ﹤0.01% 1979
2023
Q4 		$730K Sell
47,084
-3,150
-6% -$41.2K ﹤0.01% 2011
2023
Q3 		$689K Buy
50,234
+7,800
+18% +$115K ﹤0.01% 1966
2023
Q2 		$732K Buy
42,434
+2,653
+7% +$54.3K ﹤0.01% 1961
2023
Q1 		$955K Buy
39,781
+1,272
+3% +$27.7K ﹤0.01% 1811
2022
Q4 		$668K Buy
38,509
+1,747
+5% +$36.8K ﹤0.01% 1991
2022
Q3 		$896K Buy
36,762
+1,051
+3% +$36.2K ﹤0.01% 1809
2022
Q2 		$1.11M Buy
35,711
+1,395
+4% +$37.1K ﹤0.01% 1847
2022
Q1 		$1.2M Buy
34,316
+4,307
+14% +$163K ﹤0.01% 1911
2021
Q4 		$1.78M Sell
30,009
-1,352
-4% -$93.6K ﹤0.01% 1769
2021
Q3 		$2.09M Buy
31,361
+1,017
+3% +$62.7K ﹤0.01% 1707
2021
Q2 		$1.92M Buy
30,344
+298
+1% +$16.8K ﹤0.01% 1753
2021
Q1 		$1.56M Buy
30,046
+7,166
+31% +$436K ﹤0.01% 1825
2020
Q4 		$1M Buy
22,880
+6,293
+38% +$300K ﹤0.01% 1939
2020
Q3 		$786K Sell
16,587
-406,230
-96% -$16.5M ﹤0.01% 1910
2020
Q2 		$12.8M Sell
422,817
-474,478
-53% -$10.6M ﹤0.01% 1247
2020
Q1 		$15.3M Buy
897,295
+5,509
+0.6% +$96.5K ﹤0.01% 1149
2019
Q4 		$14.7M Buy
891,786
+188,600
+27% +$2.81M ﹤0.01% 1245
2019
Q3 		$11.5M Buy
703,186
+2,852
+0.4% +$57.2K ﹤0.01% 1265
2019
Q2 		$12.8M Buy
+700,334
New +$11.1M ﹤0.01% 1274

Other funds holding CYRX

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return

T. Rowe Price Associates's CYRX Position: Q1 2026 in Review

T. Rowe Price Associates increased its CryoPort (CYRX) stake by 19% in Q1 2026, buying an estimated $146K and bringing the position to 100,812 shares worth $835K. The position accounts for ﹤0.01% of the portfolio, ranked #2237.

T. Rowe Price Associates first reported a position in CYRX in Q2 2019 and has held it in 28 quarters since. The position peaked at $15.3M in Q1 2020. 165 funds tracked by Wall St. Rank hold CYRX as of Q1 2026.

  • T. Rowe Price Associates held 100,812 shares of CryoPort worth $835K as of Q1 2026.
  • T. Rowe Price Associates bought 16,144 CryoPort shares in Q1 2026, an estimated $146K.
  • CryoPort made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2237 holding.
  • T. Rowe Price Associates first reported a position in CryoPort in Q2 2019 and has held it in 28 quarters since.
  • T. Rowe Price Associates's CryoPort position peaked at $15.3M in Q1 2020.
  • 165 funds tracked by Wall St. Rank held CryoPort as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.